Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/Bf2a0a820a2c5029f4eb49c01875f9c9a> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- Bf2a0a820a2c5029f4eb49c01875f9c9a NCIT_P378 "NCI" @default.
- Bf2a0a820a2c5029f4eb49c01875f9c9a type Axiom @default.
- Bf2a0a820a2c5029f4eb49c01875f9c9a annotatedProperty IAO_0000115 @default.
- Bf2a0a820a2c5029f4eb49c01875f9c9a annotatedSource NCIT_C132295 @default.
- Bf2a0a820a2c5029f4eb49c01875f9c9a annotatedTarget "An orally bioavailable selective inhibitor of mutant forms of and fusion products involving the proto-oncogene receptor tyrosine kinase RET, with potential antineoplastic activity. Upon administration, pralsetinib binds to and targets various RET mutants and RET-containing fusion product. RET gene mutations and translocations result in the upregulation and/or activation of RET tyrosine kinase activity in various cancer cell types; dysregulation of RET activity plays a key role in the development and regression of these cancers." @default.